A randomized, partially blind, placebo controlled, crossover, single oral dose study to assess the effect of concomitant antacid (calcium carbonate / magnesium hydroxide) on the pharmacokinetics and pharmacodynamics of SMC021 (0.8 mg Salmon calcitonin/200 mg 5-CNAC) in healthy postmenopausal women

Trial Profile

A randomized, partially blind, placebo controlled, crossover, single oral dose study to assess the effect of concomitant antacid (calcium carbonate / magnesium hydroxide) on the pharmacokinetics and pharmacodynamics of SMC021 (0.8 mg Salmon calcitonin/200 mg 5-CNAC) in healthy postmenopausal women

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2012

At a glance

  • Drugs Calcitonin; Calcium carbonate; Magnesium hydroxide
  • Indications Postmenopausal osteoporosis
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Jun 2007 Status change from in progress to completed
    • 30 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top